INTRODUCTION
============

Amyloid-β (Aβ) plaques are a neuropathological feature of Alzheimer\'s disease (AD). These extracellular plaques are primarily composed of Aβ peptide aggregates generated via amyloidogenic processing of the amyloid precursor protein (APP). According to the amyloid cascade hypothesis, the Aβ peptide may play a role in AD pathology through oligomerization of the peptide. The oligomers may be directly neurotoxic or may mediate toxicity by induction of stress and hyperphosphorylation of protein tau, leading to tau aggregation into neurofibrillary tangles, cell loss, vascular damage, and dementia ([@B30]; [@B70]; [@B85]; [@B38]). Protein tau is a microtubule-associated protein that influences assembly and stabilization of microtubules. The tau protein is the main component of neurofibrillary threads and tangles (NFTs), and there is evidence supporting a key role of tau in the pathophysiology of AD. It remains to be elucidated whether tau is a bystander of amyloid toxicity or a primary mediator neurodegeneration in AD. Two major Aβ-peptide isoforms, Aβ40 and Aβ42, are generated by the amyloidogenic processing of APP, of which the latter is more hydrophobic, highly prone to aggregation and fibril formation, and more neurotoxic ([@B45]). Aβ42 is the predominant form of Aβ found in neurons ([@B31], [@B32]) and in the extracellular plaques of AD brains ([@B107]).

It is not clear whether extracellular aggregates (e.g., plaques) of Aβ lead to a protective, inert, or pathogenic mechanism. However, soluble oligomeric forms of Aβ, rather than monomeric or fibrillar forms, are the most neurotoxic species ([@B32]; [@B62]; [@B61]), and an increase of soluble oligomeric forms of Aβ42 may be an early event in AD progression ([@B32]). The role of intracellular Aβ has received increased attention ([@B35]; [@B58]). Aβ42 was found in multivesicular bodies (MVBs) of neuronal cells, where it was implicated in synaptic pathology ([@B93]). The peptide localizes to the outer membranes of MVBs ([@B93]; [@B59]) and is most often located in the perinuclear region ([@B59]). Aβ accumulation also directly inhibits the proteasome ([@B80]; [@B2]), indicating that soluble Aβ may be responsible for induction of toxicity, which may increase with impaired proteasomal function. Gradual accumulation of Aβ in mitochondria ([@B69]) has also been associated with diminished activity of electron transport chain complexes III and IV and reduced rates of oxygen utilization ([@B10]). Intracellular accumulation of Aβ precedes extracellular plaque formation, and these findings support the view that it may be an early event in the progression of AD ([@B32]). The mechanism(s) contributing to the intracellular aggregation and localization of the Aβ42 peptide in patients remains unclear. Because preventing Aβ aggregation and/or low-order oligomerization has been proposed as a potential therapeutic method ([@B32]), improved understanding of cellular processes involved in Aβ42 aggregation may help understand AD disease progression and lead to development of therapeutic strategies.

The budding yeast *Saccharomyces cerevisiae* is an important model organism for understanding many aspects of eukaryotic molecular biology. *S. cerevisiae* has been exploited to study proteins implicated in neurodegenerative disorders including Huntington\'s disease ([@B103]; [@B29]) and Parkinson\'s disease ([@B109]; [@B81]; [@B20]). Yeast model systems have been exploited to study toxicity, aggregation, and localization of Aβ or as facile systems for identification of compounds influencing Aβ oligomerization ([@B109], [@B108]; [@B56]; [@B9]; [@B66]; [@B104]; [@B96]). As indicated, protein tau has also been strongly correlated with several neuropathies, including AD. Studies of wild-type human tau in yeast have shown that the model system recapitulates several key pathological features of tau, including tau hyperphosphorylation, attainment of pathological confirmations of tau, and tau aggregation ([@B99], [@B98]). Disruption of yeast Pho85p or Mds1p, which are orthologues of human glycogen synthase kinase-3B and cdk5, influences formation of pathological phosphoepitopes of tau in yeast and their binding affinity for microtubules ([@B98]). Furthermore, deletion of *PHO85* enhances phosphorylation of the S409 residue in wild-type tau but also in tau variants associated with frontotemporal dementia with parkinsonism ([@B100]).

Green fluorescent protein (GFP)-fusion protein folding has been exploited to study the kinetics of Aβ aggregation in *Escherichia coli.* An aggregation reporter assay based on fluorescence of a fusion between Aβ42 and GFP has been developed ([@B102]). Aggregation of the GFP-fusion protein before the folding of GFP quenches its fluorescence. Expression of wild-type Aβ42 fused to GFP led to formation of insoluble aggregates in which GFP was inactive ([@B106]). Replacement of Aβ42 in the fusion protein with the less-aggregation-prone peptide Aβ40 led to increased GFP-associated fluorescence. This approach was exploited to identify variants of Aβ42 that affect aggregation of Aβ ([@B106]; [@B53]). Fluorescence intensity of Aβ-GFP fusions was inversely correlated with the aggregation propensity of the Aβ moiety, demonstrating the efficacy of using Aβ-GFP fusion-based approaches to identify factors affecting Aβ aggregation. Yeast cells expressing Aβ exhibited lower growth yield and a heat shock response, indicating that Aβ fusions cause stress in cells ([@B9]). Yeast can therefore serve as a model system to screen for modifiers of intracellular Aβ aggregation, which has relevance in understanding the role of Aβ in the death of neuronal cells. Here we exploit an aggregation reporter assay by expressing Aβ42 fused to GFP (Aβ42-GFP) in each mutant of the *S. cerevisiae* genome-wide deletion library of nonessential genes ([@B105]) to identify the cellular processes and metabolites that affect intracellular Aβ42 aggregation.

RESULTS
=======

The Aβ42-GFP fusion protein expressed in wild-type *S*. *cerevisiae* is not fluorescent, and the less amyloidogenic Aβ42-GFP variants exhibit increased fluorescence
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

In *E. coli*, the fluorescence intensity exhibited by Aβ-GFP fusions is inversely correlated with the aggregation propensity of the Aβ moiety ([@B106]; [@B53]). Mutation of Aβ residues 41 and 42 (I41E/A42P) generated a variant (AβEP-GFP) that was less aggregation prone and exhibited higher fluorescence than Aβ42-GFP or Aβ40-GFP ([@B106]). Before commencing genome-wide screening in *S. cerevisiae*, it was important to determine whether the correlations demonstrated in *E*. *coli* ([@B106]; [@B53]) between fluorescence and aggregation propensity of Aβ-GFP fusions could be recapitulated in *S. cerevisiae* cells.

Wild-type Aβ42, Aβ40, or AβEP (Aβ-I41E/A42P) sequences fused to the *N*-terminus of GFP were expressed in the cytosol of wild-type *S. cerevisiae* cells. Microscopic analysis ([Figure 1A](#F1){ref-type="fig"}) indicated that the proportion of fluorescent cells and relative fluorescence intensity per cell decreased in the order AβEP-GFP \> Aβ40-GFP \> Aβ42-GFP, which inversely correlates with the aggregation propensity of the Aβ moiety of the fusion protein. In comparison to GFP expression, which yielded fluorescence in ∼85% of wild-type cells, expression of AβEP-GFP, Aβ40-GFP, and Aβ42-GFP led to fluorescence in ∼60, 50, and 5% of cells, respectively ([Figure 1C](#F1){ref-type="fig"}). Expression of AβEP-GFP led to diffuse fluorescence distributed throughout the cytosol, whereas expression of Aβ42-GFP was associated with trace levels of cytosolic fluorescence and the presence of one to three fluorescent puncta per cell. Relative to Aβ42-GFP, expression of Aβ40-GFP led to an increase in the cytosolic fluorescence intensity and one to three puncta per cell.

![Fluorescence and corresponding light microscope images of wild-type cells expressing a GFP control vector, Aβ42-GFP, Aβ40-GFP, or AβEP-GFP. (A) Wild-type cells expressing GFP, Aβ42-GFP, Aβ40-GFP, or AβEP-GFP were induced in SC-galactose medium, and fluorescence was analyzed in exponential phase (OD~600~ of 1.5). Bar, 5 μm. (B) Western blot analysis (using 6E10 antibody) and quantification of relative band intensity of soluble (supernatant) and insoluble (pellet) cell extracts from wild-type cells expressing Aβ42-GFP, Aβ40-GFP, and AβEP-GFP grown to exponential phase (OD~600~ of 1.5). Aβ-GFP bands, ∼31 kDa. (C) Proportion of fluorescent wild-type cells expressing Aβ42-GFP, Aβ40-GFP, AβEP-GFP, or GFP (correlating with A). Nine hundred cells were counted per sample, and data shown are averages of three independent experiments. \**p* \< 0.01.](2235fig1){#F1}

To assess whether reduced fluorescence of Aβ42-GFP relative to Aβ40-GFP and AβEP-GFP was due to decreased levels of soluble (nonaggregated) Aβ-GFP, cells expressing each of the foregoing Aβ-GFP fusion constructs were grown to exponential phase in SC-galactose (inducing) medium and lysed, and soluble and insoluble proteins were fractionated by ultracentrifugation. A single band of approximately 31-kDa molecular mass reacting with an anti-Aβ antibody was detected in the insoluble pellet fraction for all strains ([Figure 1B](#F1){ref-type="fig"}), corresponding to the predicted size of the Aβ-GFP fusion protein. A band of identical molecular mass was also observed in the soluble supernatant fraction of cells expressing the Aβ40-GFP and AβEP-GFP fractions. In contrast, no band could be detected in the supernatant of cells expressing Aβ42-GFP. This result indicates that the very low levels of fluorescence in Aβ42-GFP cells were not due to lack of expression or complete proteolysis of the fusion protein. In addition, fusion protein levels in the soluble supernatant fraction were positively correlated with fluorescence, validating use of Aβ-GFP fluorescence as measure of the propensity of the fusion protein to form insoluble aggregates.

It should also be noted that a significant difference in the level of Aβ42-GFP relative to Aβ40-GFP and AβEP-GFP was observed in the insoluble fraction. Because all the Aβ-GFP fusions used were expressed from otherwise identical plasmids/promoters, reduced levels of Aβ42-GFP in cells likely stemmed from increased degradation of the insoluble aggregates of Aβ42-GFP in cells relative to Aβ40-GFP and AβEP-GFP. This hypothesis is consistent with other findings in yeast using Aβ fused to fluorescent reporters ([@B36]; [@B77]; [@B101]). The length of the linker sequence between an aggregation-prone domain and GFP influences the degree to which aggregation or misfolding inhibits the appearance of fluorescence. Fusion proteins containing longer linker sequences or where the aggregation-prone region of a multidomain protein is distal to GFP may display robust fluorescence despite forming aggregates ([@B36]). Indeed, [@B16] introduced an expanded glycine-alanine linker into their Aβ-GFP expression construct specifically to ensure that Aβ-GFP fluorescence could be observed in the endoplasmic reticulum, after failing to detect a GFP signal from a shorter linker form. Because our aim was to create a screening platform for which fluorescence was only observed under conditions in which Aβ solubility is increased, we used a very short (four amino acids) linker region between the C-terminus of Aβ and the N-terminus of GFP.

Expression of each of the respective Aβ-GFP fusions (and GFP alone) was not associated with any discernible change in growth rate of wild-type cells (unpublished data). These findings are consistent with previous findings in which amyloid was also expressed cytosolically. In yeast, cytosolic expression of wild-type Aβ42-GFP, as well as of a comprehensive set of Aβ peptide variants (fused to GFP), was not associated with any observable cytotoxicity ([@B77]; [@B101]). [@B9] reported a minor reduction (5%) in growth of yeast cells (at ∼10 h) expressing cytosolically localized Aβ42-GFP. In contrast, substantial toxicity was reported when Aβ was expressed in the endoplasmic reticulum ([@B96]; [@B16]).

Aβ42 seeds formation of punctate aggregates of Aβ40
---------------------------------------------------

Aβ toxicity has been shown to correlate with the presence of fibrils or β-sheet structures ([@B43]; [@B90]; [@B84]). However, gaps remain in understanding the mechanisms by which Aβ aggregation mediates neuronal death. Aβ aggregation proceeds by a multistep, nucleation-dependent process ([@B46]). Formation of nucleation seeds is rate limiting, and in the absence of preformed seed fibrils, there is a significant lag period for the formation of Aβ fibrils, followed by a rapid fibril elongation phase once seed fibrils have been generated. The lag time for fibril formation can be dramatically shortened by adding preformed fibril seeds to Aβ monomer ([@B46]). The rate of Aβ fibril formation is controlled by both fibril seed and monomer concentrations ([@B78]). To examine whether the more-aggregation-prone AB42-GFP affected fluorescence produced by the less-aggregation-prone AB40-GFP form, we undertook parallel expression in wild-type cells of Aβ42 plus Aβ40, Aβ42 plus AβEP, or Aβ40 plus AβEP.

Coinduction of Aβ42-GFP and Aβ40-GFP gave rise to more fluorescent cells (∼22%) than did expression of the Aβ42-GFP alone (5%) but significantly fewer than cells expressing Aβ40-GFP alone (∼40%; [Figure 2](#F2){ref-type="fig"}). Cells expressing both Aβ42-GFP and Aβ40-GFP exhibited trace cytosolic fluorescence, with intense large puncta, and in some cells there were elongated structures ([Figure 2](#F2){ref-type="fig"}). Coinduction of Aβ42-GFP and AβEP-GFP in wild-type cells also gave rise to more fluorescent cells (∼28%; exhibiting cytosolic fluorescence with small, intense puncta) compared with those expressing Aβ42-GFP alone but significantly fewer than cells expressing AβEP-GFP alone (∼70%). Coinduction of Aβ40-GFP and AβEP-GFP in wild-type cells gave rise to intense cytosolic fluorescent cells (∼60%) comparable to wild-type cells expressing AβEP alone, and 30% of the fluorescent cells contained small puncta ([Figure 2](#F2){ref-type="fig"}). The increased presence of puncta and lower levels of cytosolic fluorescence in wild-type cells coexpressing either Aβ42-GFP and Aβ40-GFP or Aβ42-GFP and AβEP-GFP indicated that the more-aggregation-prone Aβ42-GFP can act as a seed for aggregation. Preformed Aβ42-GFP aggregates formed in the cytosol may therefore accelerate nucleation and act as seeds for further formation of intracellular aggregates and fibrils.

![(A) Fluorescence microscope images of wild-type cells coexpressing Aβ42-GFP and Aβ40-GFP; Aβ42-GFP and AβEP-GFP; or Aβ40-GFP and AβEP-GFP. Wild-type cells expressing these constructs were induced in SC-galactose medium, and fluorescence was analyzed at OD~600~ of 1.5. Bar, 5 μm. (B) Proportion of fluorescent wild-type cells expressing GFP, Aβ42-GFP, Aβ40-GFP, or AβEP-GFP. Nine hundred cells were counted per sample, and data shown are averages of three independent experiments. \**p* \< 0.01.](2235fig2){#F2}

Together these data highlight the inverse correlation between the relative aggregation propensity of the Aβ moiety fused to GFP and the level of fluorescence intensity of the Aβ-GFP fusion protein in yeast cells.

Cellular processes affecting Aβ42-GFP--associated fluorescence
--------------------------------------------------------------

To identify processes affecting intracellular Aβ42-GFP aggregation, individual homozygous diploid strains of the genome-wide *S. cerevisiae* deletion library ([@B105]) were transformed with the Aβ42-GFP construct and screened using fluorescence microscopy to identify mutants exhibiting increased Aβ42-GFP--associated fluorescence and/or altered localization relative to wild-type cells. Expression of the Aβ42-GFP fusion in each strain was induced by growth in SC galactose medium (--Ura), and Aβ42-GFP--associated fluorescence was analyzed 12--18 h postinduction. Rescreening, in duplicate, of mutants that exhibited altered fluorescence during the primary screen led to identification of 344 mutants that exhibited fluorescence reproducibly different from that of the wild type. These mutants fell into two broad sets according to the intensity of fluorescence and/or percentage of fluorescent cells. The first set of 110 mutants contained those exhibiting strong fluorescence in ≥15% of cells ([Table 1](#T1){ref-type="table"}). The other 234 mutants exhibited moderate to weak fluorescence in 5--10% of cells (Supplemental Table S3). Of note, 50 of the 110 *S. cerevisiae* genes in [Table 1](#T1){ref-type="table"} have orthologues in humans.

###### 

*S. cerevisiae* genes whose deletion led to a strong increase in Aβ42-GFP--associated fluorescence, together with the respective localization of fluorescence.

  Open reading frame/gene name            Aβ42-GFP localization pattern            Respiratory deficiency   Human orthologue
  --------------------------------------- ---------------------------------------- ------------------------ ------------------
  Chromatin remodeling/histone exchange                                                                     
  *CHD1*                                  Cytosolic                                No                       CHD2
  *HIR1*                                  Single small punctate                    No                       HIRA
  *HTA2*                                  Single small punctate                    No                       H2AFX
  *SWC5*                                  Single small punctate                    No                       CFDP1
  *SWR1*                                  Multiple puncta                          No                       
  *VPS71*                                 Multiple small puncta                    No                       
  *VPS72*                                 Cytosolic with single large punctate     No                       
  *YDL041W*                               Multiple small puncta                    No                       
  Lipid metabolism/transport                                                                                
  *CHO2*                                  Cytosolic with one or two small puncta   No                       
  *DET1*                                  Cytosolic                                No                       
  *INO2*                                  ER-associated                            No                       
  *INO4*                                  Punctate                                 No                       
  *IPK1*                                  Cytosolic with single large punctate     No                       
  *OPI3*                                  ER-associated                            No                       PEMT
  *PDX3*                                  Cytosolic with punctate and nuclear      Yes                      PNPO
  *PSD1*                                  ER-associated                            No                       PISD
  *SCS2*                                  Single large punctate                    No                       VAPA
  *UME6*                                  Single small punctate                    No                       
  *YER119C-A*                             Single small punctate                    No                       
  Mitochondrial functions                                                                                   
  *ACO1*                                  Cytosolic with one or two small puncta   Yes                      ACO2
  *ACO*2                                  Cytosolic                                No                       
  *AIM4*                                  Single small punctate                    Yes                      
  *ATP11*                                 Cytosolic with one or two puncta         Yes                      ATPAF1
  *CBP3*                                  Cytosolic with puncta                    Yes                      UQCC
  *CIT1*                                  Cytosolic with one or two small puncta   Yes                      
  *CIT3*                                  Cytosolic with one or two small puncta   No                       
  *COX16*                                 Cytosolic                                Yes                      
  *COX20*                                 Cytosolic                                Yes                      
  *CYM1*                                  Single small punctate                    No                       PITRM1
  *FUM1*                                  Cytosolic with puncta                    Yes                      FH
  *HAP2*                                  Cytosolic                                Yes                      NFYA
  *HAP3*                                  Single small punctate                    Yes                      NFYB
  *IDH1*                                  Cytosolic with small puncta              Yes                      IDH3B
  *IDH2*                                  Cytosolic with small puncta              Yes                      IDH3A
  *IDP1*                                  Cytosolic with small puncta              No                       IDH1
  *KGD1*                                  Cytosolic                                Yes                      OGDH
  *KGD2*                                  Cytosolic                                Yes                      DLST
  *LPD1*                                  Cytosolic                                Yes                      DLD
  *LSC1*                                  Cytosolic                                Yes                      SUCLG1
  *LSC2*                                  Cytosolic                                No                       
  *MDH1*                                  Cytosolic                                No                       MDH2
  *MIC14*                                 Cytosolic                                No                       
  *MRPL35*                                Cytosolic                                Yes                      MRPL35
  *MRPL7*                                 Cytosolic with small puncta              Yes                      
  *PET112*                                Single small punctate                    Yes                      PET112L
  *PET117*                                Cytosolic                                Yes                      
  *PYC1*                                  Cytosolic with small puncta              No                       PC
  *PYC2*                                  Cytosolic                                No                       PC
  *RIM1*                                  Cytosolic                                Yes                      
  *RRG8*                                  Large punctate and nuclear-diffused      Yes                      
  *RSM18*                                 Single small punctate                    Yes                      
  *RSM7*                                  Cytosolic                                Yes                      
  *SDH1*                                  Cytosolic                                No                       SDHA
  *SDH2*                                  Cytosolic                                Yes                      SDHB
  *SDH4*                                  Cytosolic with puncta                    Yes                      SDHD
  *STF2*                                  Cytosolic with single large punctate     No                       
  *TUF1*                                  Single small punctate                    Yes                      TUFM
  *YDR230W*                               Cytosolic                                Yes                      
  Gene expression/regulation                                                                                
  *CTK1*                                  One or two small puncta                  No                       
  *DEG1*                                  Single large punctate                    No                       PUS3
  *ELC1*                                  Single small punctate                    No                       
  *GAT1*                                  Single small punctate                    No                       
  *GDT1*                                  Single small punctate                    Yes                      TMEM165
  *HFI1*                                  Cytosolic                                Yes                      
  *LSM7*                                  Multiple small puncta                    Yes                      LSM7
  *MED1*                                  Cytosolic with one or two small puncta   No                       MED1
  *MOT2*                                  Single small punctate                    Yes                      
  *NCL1*                                  Single small punctate                    No                       NSUN2
  *SNT309*                                Cytosolic with one or two small puncta   Yes                      
  *SRB8*                                  One or two small puncta                  Yes                      MED12L
  *SSN2*                                  Cytosolic with single large punctate     No                       MED13L
  *SSN3*                                  Multiple small puncta                    Yes                      CDK8
  *SYC1*                                  Single small punctate                    No                       
  *TIF4631*                               Multiple small puncta                    Yes                      EIF4G1
  Mitotic cell cycle                                                                                        
  *CTS1*                                  Cytosolic                                No                       
  *DCC1*                                  Single small punctate                    Yes                      DSCC1
  *POG1*                                  Single small punctate                    No                       
  *SWI4*                                  Cytosolic with single small punctate     No                       
  Methionine metabolism                                                                                     
  *MET16*                                 Single small punctate                    No                       
  *MET8*                                  Single small punctate                    No                       
  *MXR1*                                  Single small punctate                    No                       MSRA
  Purine metabolism                                                                                         
  *ADE12*                                 Single small punctate                    No                       ADSSL1
  *ADK1*                                  Single small punctate                    No                       AK2
  Spindle pole body                                                                                         
  *BFA1*                                  Single small punctate                    No                       
  *BIM1*                                  Single small punctate                    No                       MAPRE1
  Ubiquitin/proteasome                                                                                      
  *SAN1*                                  Cytosolic                                No                       
  *SHP1*                                  Cytosolic with puncta                    Yes                      NSFL1C
  *UBR1*                                  Cytosol with large punctate              No                       UBR1
  Bud-site selection                                                                                        
  *BUD23*                                 Cytosolic with punctate                  Yes                      WBSCR22
  *BUD31*                                 Cytosolic with puncta                    Yes                      BUD31
  MAP kinase activity                                                                                       
  *PBS2*                                  Single small punctate                    No                       MAP2K4
  *SLG1*                                  Single small punctate                    No                       
  *SOK1*                                  Multiple small puncta                    No                       
  Others/unknown                                                                                            
  *APJ1*                                  Single small punctate                    No                       
  *ASM4*                                  Cytosolic with large punctate            No                       
  *EMI2*                                  Cytosolic with small puncta              No                       
  *GTT3*                                  Single small punctate                    No                       
  *ICE2*                                  ER-associated                            No                       
  *ICY2*                                  Single small punctate                    No                       
  *PAU11*                                 Cytosolic                                No                       
  *PHM6*                                  Cytosolic puncta                         No                       
  *RAD61*                                 Cytosolic punctate                       No                       
  *RIB1*                                  Multiple puncta                          Yes                      
  *RKM4*                                  Single small punctate                    No                       
  *SNX41*                                 Cytosolic with one or two small puncta   No                       
  *YDL242W*                               Cytosolic                                No                       
  *YDR015C*                               Cytosolic                                No                       
  *YEL008W*                               Single small punctate                    No                       
  *YIM2*                                  Cytosolic                                No                       
  *YOR364W*                               Single small Punctate                    No                       

Because many *S. cerevisiae* genes have human orthologues, identification of these may help to identify cellular processes in humans that play a role in Aβ42 aggregation. Of the 110 *S. cerevisiae* genes in [Table 1](#T1){ref-type="table"}, 50 have human orthologues identified using the National Center for Biotechnology Information database, HomoloGene. These genes may provide a point for more targeted studies in mammalian AD model systems.

Five distinct Aβ42-GFP localization patterns were observed among the 110 mutants identified by the genome-wide screen ([Figure 3](#F3){ref-type="fig"}): single punctate (29%), multiple puncta (9%), cytosolic-diffuse (22%), distinct arc-shaped (5%), and a combination of punctate and cytosolic-diffuse fluorescence (35%). The percentages are based on the number of mutants in each group. An example of each of these localization patterns is given in [Figure 3](#F3){ref-type="fig"}.

![Fluorescence microscope images of representative mutants exhibiting various Aβ42-GFP localization patterns. Strains expressing Aβ42EGFP were induced in SC-galactose medium, and Aβ42-GFP--associated fluorescence was analyzed between 12 and 18 h postinduction (OD~600~ of ∼1.5). The Aβ42-GFP--associated localization patterns were classified as (A) fluorescent punctate, (B) multiple fluorescent puncta, (C) cytosolic-diffuse fluorescence, (D) arc-shaped perinuclear fluorescence, and (E) combination of puncta and cytosolic fluorescence. Arrows indicate the specific type of localization in each of the mutants. Bar, 5 μm. (F) Graphic representation of cellular processes identified affecting Aβ42-GFP--associated fluorescence in *S*. *cerevisiae*. Percentages reflect the number of mutants identified in a particular cellular process relative to the total number of mutants identified by the genome-wide screen.](2235fig3){#F3}

Functional categories overrepresented in the group of 110 genes indicated the main cellular processes likely to affect intracellular Aβ42 aggregation. Manual inspection of the list identified processes including phospholipid metabolism, mitochondrial function, and chromatin remodeling. In addition, histone exchange (*p* = 2.12 × 10^−5^), DNA-dependent transcription (*p* = 0.0009), chromatin remodeling (*p* = 0.009) and modification (*p* = 0.001), and tricarboxylic acid (TCA) cycle (*p* \> 1 × 10^−14^) functions were significantly overrepresented using SGD FunCat GO Term Finder. Analysis using Munich Information Centre for Protein Sequences (MIPS) FunCatDB yielded a very similar set of functional categories but also identified phosphatidylcholine (PC) biosynthesis/phospholipid metabolism (*p* = 0.001), regulation of lipid, fatty acid, and isoprenoid metabolism (*p* = 0.008), sulfate assimilation (*p* = 0.007), and transcriptional control (*p* = 0.0005) to be overrepresented ([Figure 3](#F3){ref-type="fig"}).

Of the 110 mutants identified in the genome-wide screen, 35% (39 mutants from 110) were annotated in the *Saccharomyces* Genome Database as exhibiting disrupted mitochondrial respiratory function. Analysis of process ontology identified acetyl-CoA catabolism and enzymes of the TCA cycle, including isocitrate dehydrogenase (Idp1p), α-ketoglutarate dehydrogenase (Kgd2p), succinate dehydrogenase (Sdh4p), aconitase (Aco1p), and fumarase (Fum1p) to be significantly overrepresented (*p* = 7.71 × 10^−22^). Fluorescent Aβ42-GFP in TCA cycle mutants was cytosolic-diffuse, or cytosolic-diffuse with single to multiple small puncta ([Figure 4](#F4){ref-type="fig"}), which did not appear to occur in a distinct structure in the cell. Mitochondrial mutants that had strongly affected Aβ42-GFP--associated fluorescence were mainly defective in metabolism of pyruvate to oxaloacetate and disruption of the TCA cycle. It was previously demonstrated that 341 nuclear genes affect respiratory growth capacity and/or mitochondrial morphology, including numerous genes encoding subunits of the mitochondrial electron transport chain complexes and factors required for their assembly, enzymes of the TCA cycle, mitochondrial ribosome function and maintenance, and inheritance of the mitochondrial genome ([@B15]). In the event that some mutants may have been missed in the initial screen, a comprehensive rescreening of representative mutants affected in mitochondrial functions was undertaken and Aβ42-GFP--associated fluorescence reassessed in each strain. These analyses not only validated the 39 mitochondrial mutants identified in the initial screen as having strongly affected Aβ42-GFP--associated fluorescence, but they also confirmed that loss of many other genes involved in mitochondrial functions, including respiratory energy production, mitochondrial ribosome function, and mitochondrial genome maintenance, did not affect Aβ42-GFP fluorescence in the same manner. Of those ∼30 non-TCA cycle mutants that were affected in Aβ42-GFP fluorescence, the effect was comparatively weak in terms of fluorescence intensity and the proportion of affected cells in a given population (Supplemental Table S3).

![Fluorescence microscope images of mutants expressing Aβ42-GFP induced in galactose medium, and analysis of Aβ42-GFP--associated fluorescence (OD~600~ of ∼1.5). (A) *Δaco1*, (B) *Δfum1*, (C) *Δidp1*, (D) *Δkgd2*, and (E) *Δsdh4* predominantly exhibit cytosolic-diffuse Aβ42-GFP--associated fluorescence, with some mutants exhibiting fluorescent puncta. Phospholipid mutants (F) *Δopi3*, (G) *Δpsd1*, (H) *Δcho2*, and (I) *Δino2*. Aβ42-GFP-associated fluorescence in wild-type cells overexpressing (J) *INM1* cytosolic diffuse, (K) *INM2* cytosolic diffuse, or (L) *CDS1* exhibiting perinuclear Aβ42-GFP localization. Arrows point to a distinct localization pattern. Bar, 5 μm](2235fig4){#F4}

The mitochondrial genome (mtDNA) of *S. cerevisiae* encodes eight proteins that are essential for oxidative phosphorylation ([@B97]), and deletion of mtDNA leads to respiratory incompetence due to disruption of the mitochondrial electron transport chain. *S. cerevisiae* is a facultative aerobe, and respiratory-incompetent cells can grow on carbon sources such as glucose or galactose. To further examine whether the disruption of respiratory function per se affected Aβ42-GFP fluorescence, we grew rho-zero (rho^0^) cells lacking mtDNA derived from wild-type (BY4743) *S. cerevisiae* in SC galactose (inducing) medium and analyzed the effect on Aβ42-GFP. Respiratory-incompetent rho^0^ cells yielded similar trace levels of Aβ42-GFP fluorescence (∼5%), comparable to wild-type grande cells, indicating that loss of respiratory function per se does not affect Aβ42-GFP--associated fluorescence.

Many mutants affected in mitochondrial function, including those affected in operation of the TCA cycle, exhibit a reduced growth rate ([@B26]; [@B72]), and this may have indirectly influenced Aβ42-GFP fluorescence in the present screen. However, this explanation is unlikely, since there was complete lack of correlation between the genes identified in the present study and ∼720 yeast genes whose deletion was previously shown to cause slow growth ([@B26]; [@B40]), and, more broadly, the ∼340 genes identified previously that are involved in mitochondrial morphology and/or respiration. Mitochondrial dysfunction in rho^0^ cells has been shown to promote increased Gal4-dependent transcription ([@B47]). Loss of mitochondrial function was not a primary cause of increased Aβ42-GFP fluorescence in the mitochondrial mutants, since rho^0^ cells exhibited the same Aβ42-GFP fluorescence as the wild-type parent. These data support the hypothesis that loss of distinct mitochondrial functions, including those involved in TCA cycle function, metabolism of pyruvate to oxaloacetate, and cytochrome *c* oxidase activity, leads to increased Aβ42-GFP--associated fluorescence and thus influences Aβ aggregation.

Disruption of genes involved in the TCA cycle leads to altered expression of ∼400 genes, including decreased expression of genes involved in glucose uptake (*HXT7, HXT6*), glycolysis (*PFK26, FBP26*), and glycogen/trehalose production (*GDB1, GPH1, GSY1, TPS1, TSL1*), and, conversely, induction of genes involved in inositol or phosphatidylcholine biosynthesis biosynthesis (*INO1*, *OPI3*; [@B72]). Induction of *INO1* and *OPI3* does not occur in rho^0^ cells ([@B19]; [@B95]). This raised the possibility that increased inositol synthesis may lead to increased Aβ42-GFP fluorescence. To examine this hypothesis more directly, we assessed the effect on Aβ42-GFP fluorescence in wild-type BG1805 cells grown to exponential phase (SC galactose --URA--HIS) of overexpressing genes encoding Ino1p (inositol-3-phosphate synthetase) or Inm1p or Inm2p (inositol monophosphatase), which perform subsequent steps in inositol biosynthesis. Strikingly, overexpression of either *INM1* or *INM2* led to intense diffuse fluorescence in ∼18% of cells compared with the empty vector control and cells overexpressing *INO1*, in which only trace fluorescence was observed ([Figure 4](#F4){ref-type="fig"}). Although these data do not establish a direct causal link between increased Aβ42-GFP fluorescence in mutants disrupted in TCA function and altered inositol synthesis, it is worth noting that both situations led to the appearance of intense diffuse Aβ42-GFP fluorescence in cells. The broader implications of these data are addressed further in the *Discussion*.

Phospholipid homeostasis plays an important role in intracellular aggregation of Aβ42-GFP
-----------------------------------------------------------------------------------------

Of the Aβ42-GFP localization patterns identified, the arc-shaped fluorescence localization in mutants affected in phospholipid homeostasis was distinctive, and these mutants were selected for further investigation. Five deletion mutants expressing Aβ42-GFP exhibited structured arc-shaped Aβ42-GFP fluorescence ([Figure 4](#F4){ref-type="fig"}). Of the five genes involved, three encode consecutive steps in the conversion of phosphatidylserine to phosphatidylcholine (phosphatidylserine decarboxylase, *PSD1*; and phosphatidylethanolamine methyltransferases, *CHO2* and *OPI3*) and two (*INO2* and *INO4*) encode a heterodimeric transcriptional regulator of phospholipid and inositol biosynthesis ([@B3]). From [Figure 5](#F5){ref-type="fig"}, Aβ42-GFP or Aβ40-GFP were localized in a perinuclear location in the Δ*opi3* mutant. These data indicate that the perinuclear localization of Aβ42-GFP and Aβ40-GFP did not depend on the last two residues of the Aβ moiety in the former. High-resolution confocal microscopy indicated that in Δ*opi3* cells the perinuclear fluorescence consisted of numerous intense puncta localized around the nucleus ([Figure 5](#F5){ref-type="fig"}). The elongated cell morphology observed with the Δ*opi3* mutant was not due to induction of AβGFP fusion proteins, since it was also observed in otherwise genetically identical cells expressing the empty vector control (pUG35GAL1; see Supplemental Figure S1).

![Aβ-GFP localization in the Δ*opi3* mutant. (A) *Δopi3* cells expressing Aβ42-GFP or Aβ40-GFP (green) were grown in galactose medium, and fluorescence was analyzed. Cells were costained with DAPI (blue) to visualize the nucleus, indicating the perinuclear localization of Aβ42-GFP or Aβ40-GFP in Δ*opi3* cells. (B) Confocal microscopic image of a *Δopi3* cell expressing Aβ42-GFP (green) stained with DAPI (blue). Bar, 5 μm. (C) Western blot analysis, using the 6E10 antibody, of subcellular fractions of the ER and mitochondria from wild-type and *Δopi3* cells expressing Aβ42-GFP. Aβ42-GFP band, ∼31 kDa. Antibodies against Por1p and Wbp1p were used as controls to validate lack of cross-contamination between mitochondria and ER fractions, respectively. Dotted lines delineate individual lanes on gels.](2235fig5){#F5}

To investigate more precisely the localization of the fluorescent Aβ42-GFP in the Δ*opi3* cells, wild-type and Δ*opi3* cells expressing the Aβ42-GFP fusion construct were grown to exponential phase, and subcellular fractionation of endoplasmic reticulum (ER) and mitochondria was performed. Aβ42-GFP was detected via Western blot using the 6E10 antibody. In wild-type cells, a ∼31-kDa Aβ42-GFP band was mainly observed in the mitochondrial fraction, with a very faint band also visible in the ER fraction ([Figure 5](#F5){ref-type="fig"}). In contrast, Δ*opi3* cells expressing Aβ42-GFP exhibited intense ∼31-kDa bands corresponding to Aβ42-GFP in both the ER and mitochondrial fractions. The Aβ42-GFP identified in the mitochondrial fraction by cell fractionation and immunoblotting was therefore nonfluorescent aggregated Aβ42-GFP, since Aβ42-GFP--associated fluorescence was not observed in the mitochondria in whole cells via microscopic analysis. Owing to the appearance of an intense band of Aβ42-GFP in the mitochondrial fraction in both the wild type and the Δ*opi3* mutant, the possibility that aggregated Aβ42-GFP may have simply cosedimented with the mitochondrial fraction cannot be ruled out. Taken together with the data from Western blotting, which would detect both fluorescent and aggregated nonfluorescent Aβ42-GFP, these data support the proposal that fluorescent Aβ42-GFP in Δ*opi3* cells may be localized to the ER/ER membrane. Because nonaggregated/soluble Aβ-GFP correlated with fluorescence intensity ([Figure 1](#F1){ref-type="fig"}), these data also support the proposal that it was the soluble form of Aβ42-GFP that had interacted with the ER/ER membrane. These data strongly implicate phospholipid metabolism/homeostasis as an effector of Aβ42 aggregation. Given the role of phospholipids as structural components of cell membranes, disruption of phospholipid homeostasis---for example, as in Δ*opi3* cells, influences the interaction of "soluble" Aβ42 (and probably Aβ40) with the ER membrane, influencing Aβ aggregation. These data are of particular interest, given the localization of many steps of phospholipid synthesis to the ER.

An alternative route of PC synthesis, via the Kennedy salvage pathway, depends on the availability of precursor molecules, including ethanolamine (EA), monomethylethanolamine, dimethylethanolamine (DMEA), or choline ([@B91]; [@B73]). Because the growth medium used in mutant screening did not contain any of these substrates, it is likely that the membranes of Δ*psd1*, Δ*opi3* mutants were depleted in PC and/or additional phospholipids and that this was associated with altered Aβ42-GFP--associated fluorescence. To test this, Δ*opi3* cells expressing Aβ42-GFP or GFP alone were cultured in media supplemented with 1 mM EA, DMEA, or choline. Media supplementation with 1 mM DMEA or choline ([Figure 6](#F6){ref-type="fig"}) resulted in reversal to a wild-type phenotype ([Figures 6](#F6){ref-type="fig"} and [1](#F1){ref-type="fig"}) for Δ*opi3* cells, with a comparable level of fluorescence to the wild-type strain. In contrast, treatment of Δ*opi3* cells with EA did not lead to altered fluorescence relative to untreated cells. This is consistent with the capacity of Opi3p to methylate either phosphatidyldimethylethanolamine or phosphatidylmonomethylethanolamine but not phosphatidylethanolamine, leading to PC formation. Treatment of cells expressing GFP alone in a comparable manner did not lead to any difference in fluorescence. The perinuclear localization of Aβ42-GFP fluorescence in Δ*opi3* cells therefore appears to be related to their capacity to maintain PC homeostasis.

![Fluorescence microscopic images of *Δopi3* cells expressing GFP or Aβ42-GFP grown in galactose (induction) medium either lacking or supplemented with 1 mM ethanolamine (EA), dimethylethanolamine (DMEA), or choline. Cells were analyzed for fluorescence in exponential phase (OD~600~ of ∼1.5). Bar, 5 μm.](2235fig6){#F6}

Overexpression of *CDS1*, encoding cytidine diphosphate--diacylglycerol synthase, alters Aβ42-GFP--associated fluorescence
--------------------------------------------------------------------------------------------------------------------------

To obtain further insight into the link between altered phospholipid homeostasis and Aβ42-GFP fluorescence, we assessed the effect of overexpressing genes involved in phospholipid metabolism on Aβ42-GFP. Wild-type cells were transformed with the plasmids carrying one of each of numerous genes involved in lipid metabolism (listed in Supplemental Table S4) and the cells examined to identify those exhibiting increased Aβ42-GFP--associated fluorescence and/or altered fluorescence morphology. Cells with the plasmids that encode proteins involved in lipid synthesis/regulation were cotransformed with the pAβ42-GFP construct in corresponding deletion mutant strains, as well as in wild-type cells. Expression of the Aβ42-GFP fusion protein and the lipid-related gene in each strain was induced by growth in galactose medium, and Aβ42-GFP--associated fluorescence was analyzed 12--18 h postinduction.

Cells overexpressing *CDS1* exhibited ordered localization of intensely fluorescent puncta of Aβ42-GFP in a perinuclear arrangement analogous to that seen in the Δ*psd1*, Δ*cho2*, and Δ*opi3* mutants ([Figure 4](#F4){ref-type="fig"}). *CDS1* encodes CDP-DAG synthase, which catalyzes CDP-DAG--dependent synthesis of phospholipids from phosphatidic acid ([@B42]). These data further support that Aβ42-GFP aggregation is strongly influenced by altered phospholipid homeostasis in *S. cerevisiae* cells.

DISCUSSION
==========

The finding that fluorescence of an Aβ-GFP fusion protein is inversely proportional to its propensity to aggregate in *E. coli* ([@B53], [@B54]) provides an elegant and adaptable approach for exploring the intracellular properties of Aβ. The present study demonstrates that when expressed in the cytosol of the yeast *S. cerevisiae*, the inverse relationship between Aβ-GFP fluorescence and aggregation potential is preserved. This system forms the foundation of a genetically tractable eukaryotic platform for identifying processes that affect intracellular Aβ aggregation, an important feature in the pathology of Alzheimer\'s disease. We transformed an Aβ42-GFP expression plasmid into the entire *S. cerevisiae* genome deletion mutant collection and examined individual mutants for changes in Aβ42-GFP fluorescence. Conversely, we also overexpressed a targeted panel of genes in wild-type cells expressing Aβ42-GFP and examined the effect on fluorescence.

This approach identified 110 deletion mutants exhibiting strong Aβ42-GFP--associated fluorescence and 234 deletion mutants that exhibited weak fluorescence. After clustering mutants into broad functional categories, three emerged as being significantly overrepresented: mitochondrial function, phospholipid metabolism, and transcriptional/translational regulation. Overexpression of the genes *CDS1*, *INM1*, and *INM2* significantly increased fluorescence in Aβ42-GFP--expressing wild-type cells, additionally implicating inositol biosynthesis as a fourth functional class.

These functional categories parallel some of those affected in Alzheimer\'s disease patients, and several genes identified in our screen have human homologues that have been found to be directly related to Aβ and Alzheimer\'s pathology. Mutants affected in mitochondrial function and tricarboxylic acid cycle function exhibited the highest changes in fluorescence identified in the screen (both intensity and proportion of cells), mirroring the long association of mitochondrial dysfunction with Alzheimer\'s pathology ([@B14]; [@B4]). Human homologues of the yeast TCA cycle screen hits α-ketoglutarate dehydrogenase (*KGD2*) and isocitrate dehydrogenase (*IDP1*) show reduced activity in AD patient brains, with the extent of reduction correlating closely with decreased mental performance ([@B28], [@B27]; [@B57]; [@B8]; [@B11]). Decreased activity of α-ketoglutarate dehydrogenase leads to sensitivity to oxidative damage, which is strongly associated with AD ([@B88]). Given that rho^0^ respiratory-deficient cells and a range of other mitochondrial mutants displayed wild-type Aβ42-GFP fluorescence, altered Aβ aggregation appears to be specifically linked to TCA cycle and oxaloacetate-to-pyruvate defects.

One potential explanation for this may relate to inositol metabolism. In yeast, disruption of TCA function increases expression of inositol-3-phosphate synthase (encoded by *INO1*), a key enzyme in inositol synthesis ([@B72]). We demonstrated that overexpression of either of the *myo*-inositol biosynthetic genes *INM1* or *INM2* led to the appearance of similar intense, diffuse Aβ42-GFP fluorescence as observed in the TCA cycle mutants, suggesting a link between inositol metabolism, the TCA cycle, and Aβ aggregation. In human brain, *myo*-inositol is the most abundant stereoisomer ([@B39]) and forms small stable micelles with the Aβ peptide ([@B75]). Amyloid fibril formation is inhibited by *myo*-inositol ([@B24]), and complexation of Aβ with inositol protects neuronal cultures from Aβ toxicity ([@B76]). Similarly, the *scyllo*-inositol stereoisomer inhibits amyloid formation ([@B63]; [@B71]), and treatment of animal AD models with *scyllo*-inositol reduces plaque formation and improves memory performance and hippocampal synaptic plasticity ([@B74]; [@B5]). Of note, the activity of the human *myo*-inositol monophosphatase homologue of the yeast *INM1*/*INM2* genes identified in this study is raised in the brains of AD patients, possibly reflecting a compensatory change to altered phospholipid metabolism ([@B87]). Furthermore, *scyllo*-inositol was previously identified as an inhibitor of Aβ oligomerization in yeast ([@B82]). Our results, together with those previously reported, suggest that inositol metabolism modulates the aggregation of the Aβ peptide and offer a potential link to the increased Aβ42-GFP fluorescence observed in TCA cycle mutants. Increased inositol levels resulting in formation of soluble inositol/Aβ42-GFP micelles and inhibition of Aβ42-GFP oligomerization offers a potential mechanistic explanation for the significant fluorescence observed in *INM1*/*INM2*-overexpressing cells.

In addition to alteration of inositol production, TCA cycle dysfunction would also affect NAD^+^/NADH homeostasis. NAD^+^ availability may modulate sirtuin-2 activity, leading to altered Aβ deposition, tubulin deacetylation, and potentiation of tau hyperphosphorylation ([@B89]). Given the role of sirtuins in chromatin remodeling, it is interesting to note that our screen identified numerous mutants affected in similar functions, particularly those affecting the Swr1 chromatin remodeling complex, suggesting the existence of a potential link between Aβ aggregation, TCA metabolite levels, and chromatin dynamics.

Several mutants affecting phospholipid synthesis exhibited increased Aβ42-GFP fluorescence in our screen. There is strong evidence of perturbed phospholipid metabolism in AD patients ([@B44]; [@B22]; [@B34]). Phosphatidylcholine levels are reduced in cortical membranes ([@B79]) and erythrocytes ([@B86]) of AD patients, and studies of the global brain and plasma lipidomes in mouse AD models revealed changes in several sterol, sphingolipid, and phospholipid species, each occurring at specific stages of AD progression ([@B92]). Deletion mutants identified in our screen related to phospholipid metabolism included enzymes involved in the de novo synthesis of phosphatidylcholine from phosphatidylserine and phosphatidylethanolamine (PE; *PSD1*, *CHO2* and *OPI3*; [@B55]; [@B91]; [@B73]) and both members of a heterodimeric transcription complex positively regulating the transcription of a large family of phospholipid biosynthetic genes (including *OPI3*; [@B65]; [@B41]; [@B6]; [@B48]).

Defects in these PC biosynthetic pathways lead to accumulation of PC precursors, such as PE and phosphatidylmonomethylethanolamine and altered membrane composition ([@B52]). Supplementation with choline or dimethylethanolamine restores normal synthesis of PC via the Kennedy salvage pathway ([@B52]; [@B73]) and, in this study, significantly reduced Aβ42-GFP fluorescence in Δ*opi3* cells. Of interest, mutations in *PEMT*, the human homologue of yeast *OPI3*, are associated with increased risk of developing AD ([@B7]). *SCS2* encodes a key ER regulator of inositol and phospholipid metabolism ([@B33]; [@B49]; [@B23]; [@B64]), with Δ*scs2* mutants accumulating 10% more PC than wild-type cells ([@B50]). Thus, the intense Aβ42-GFP fluorescence in Δ*scs2* mutants indicates that PC depletion alone is unlikely to be the underlying cause of altered Aβ42-GFP fluorescence in Δ*opi3* and Δ*cho2* cells. We demonstrated that overexpression of CDP-diacylglycerol synthase (*CDS1*), responsible for synthesis of the global phospholipid precursor CDP-diacylglycerol, also resulted in increased Aβ42-GFP fluorescence. Together these results indicate overall perturbation of normal phospholipid homeostasis and membrane composition rather than changes in a single lipid species as being an important regulator of Aβ aggregation.

Aβ40/42 peptides may be absorbed onto phospholipid membranes ([@B94]; [@B51]; [@B17]; [@B18]), and there is strong evidence that lipid composition modulates the association, dissociation, and aggregation of Aβ on membranes ([@B67]; [@B68]; [@B12]; [@B37]; [@B60]). The influence of membrane composition on Aβ dynamics suggests a mechanism for the changes in Aβ42-GFP fluorescence observed in *Δino2*, *Δino4*, *Δpsd1*, *Δopi3*, and *Δcho2* mutants and *CDS1*-overexpressing cells. In these strains, disrupted lipid homeostasis alters normal membrane composition, including incorporation of intermediates of phospholipid biosynthetic pathways. Aβ42-GFP interaction with these membranes may be altered, favoring reduced aggregation of Aβ and increased fluorescence. The distinctive perinuclear ER membrane--like localization of Aβ42-GFP fluorescence in these strains indicates that such compositional changes are localized to specific organelles or subcellular regions. A detailed subcellular lipidomic analysis of organelle-specific membranes may provide data to further test this hypothesis, allowing in vitro measurement of Aβ aggregation on synthetic membranes, with compositions matched to those of the mutants.

This study identifies specific genes and broader functional classes that influence the aggregation of an Aβ42-GFP fusion protein in the cytosol of yeast, complementing recent screens focusing on intracellular Aβ toxicity ([@B96]; [@B16]. We found that deletion of *PBS2*, encoding a mitogen-activated protein (MAP) kinase of the high osmolarity glycerol (HOG) pathway, resulted in the appearance of a single intense, punctate fluorescent Aβ42-GFP structure in cells, and [@B96] determined that overexpression of *PBS2* enhanced toxicity of Aβ expressed in the yeast endoplasmic reticulum and that expression of the human *PBS2* homologue, MAP2K4, in a *Caenorhabditis elegans* neuronal model resulted in enhanced cell death. These complementary results together suggest that altered intracellular Aβ aggregation may contribute to Aβ-induced cell toxicity in which signaling in the HOG pathway is compromised. The high concordance of functional classes identified in our screen with those affected in animal AD models and AD patients, particularly related to the TCA cycle, inositol metabolism, and phospholipid homeostasis, hints at the involvement of novel modulators of intracellular Aβ aggregation in the development of the disease in humans.

MATERIALS AND METHODS
=====================

Strains and culture conditions
------------------------------

*S. cerevisiae* homozygous diploid deletants for all nonessential genes were obtained from the European *Saccharomyces cerevisiae* Archive for Functional Analysis ([@B105]). These deletants were produced in the BY4743 diploid strain background (*MAT***a***/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 met15Δ0/MET15 LYS2/lys2Δ0 ura3Δ0/ura3Δ0*), which was used as the wild-type reference strain. Standard yeast growth media and techniques were used throughout this study. Yeast strains were grown in YEPD medium (2% \[wt/vol\] glucose, 2% \[wt/vol\] peptone, 1% yeast extract) or synthetic defined complete medium (SC; 2% \[wt/vol\] glucose, 0.17% yeast nitrogen base without amino acids \[Becton Dickinson, Franklin Lakes, NJ\], 5% \[wt/vol\] ammonium sulfate \[Sigma, St. Louis, MO\]) supplemented with appropriate amino acids and bases as indicated in Supplemental Table S1. Expression of genes under the control of the *GAL1* promoter was induced by growth in induction medium (SC-galactose; SC medium with 2% \[wt/vol\] galactose instead of glucose). Where required, filter-sterilized phospholipid precursors were added to SC or induction media at 1 mM final concentration. Respiratory-incompetent (rho^0^) cells, lacking mitochondrial DNA, were generated by ethidium bromide treatment of the wild-type strain ([@B21]), identified by their inability to grow on YEPG medium and confirmed by a lack of mitochondrial DNA, visualized using 4,6-diamidino-2-phenylindole dihydrochloride (DAPI \[Sigma\]). At least five independent rho^0^ cells generated were examined for each experiment. Unless otherwise stated, all other reagents were purchased from Sigma.

Plasmid construction
--------------------

A derivative of the pUG35GFP fusion vector ([http://mips.gsf.de/proj/yeast/info/tools/hegemann/gfp.html](http://mips.gsf.de/proj/yeast/info/tools/hege)) containing the *GAL1* promoter was created by excising the *MET25* promoter from pUG35 by digestion with *Sac*I and *Xba*I. The *GAL1* promoter was amplified from a pESC-URA template (Stratagene), using primers ESC-URA-F and ESC-URA-R (Supplemental Table S2) containing *Sac*I and *Xba*I restriction sites, respectively. The fragment containing *GAL1* was ligated into pUG35 to produce pUG35GAL1. To generate Aβ-GFP fusion constructs for the deletion library screen, Aβ42 coding sequence was amplified using pAS1N.AβGFP plasmid DNA ([@B9]) as a template. The *C*-terminus of Aβ42 was fused to the N-terminus of GFP (including a four--amino acid linker) by amplifying the Aβ42 coding sequence, using primers ABETA-F and ABETA-R containing *Bam*HI and *Sal*I sites, respectively. After digestion with these enzymes, the Aβ42 fragment was ligated into pUG35GAL1 to produce plasmid pAβ42-GFP. Similarly, GFP fusions of the C-terminally truncated Aβ40-GFP and a mutant form of Aβ42 (with amino acid substitutions I41E and A42P) were created by amplification using ABETA-F with ABETA-40-R and ABETA-EP-R primers, respectively, to yield pAβ42-GFP and pAβEP-GFP. To generate Aβ-GFP fusion constructs for the overexpression screen, the respective PCR fragments were used for the BP reaction of the Gateway system (Invitrogen, San Diego, CA) with the destination vector pDonr221. The resulting plasmids, pDonr221-Aβ42-GFP/pDonr221-Aβ40-GFP/pDonr221-AβEP-GFP/pDonr221-EGFP, were used for the LR reaction using the destination vector pAG415GAL-ccdB and pAG416GAL-ccdB ([@B1]). Plasmids were maintained and amplified in *E. coli* DH5-α cells. For gene overexpression experiments, high-copy galactose-inducible plasmids of the Yeast ORF Collection containing *S. cerevisiae* open reading frames in the BG1805 plasmid background were used ([@B25]; Thermo Scientific).

Protein extraction, SDS--PAGE, and Western blot analysis
--------------------------------------------------------

Yeast cultures (50 ml) were grown to OD~600~ of 1.5 in induction medium (SC-galactose) lacking uracil at 30°C. Cells were harvested, washed with water, and lysed by shaking with glass beads in ice-cold lysis buffer (0.1 mM Tris-HCl, pH 8.0) supplemented with protease inhibitors (Complete; Roche). Intact cells and large debris were removed by centrifugation at 2000 rpm for 5 min at 4°C. Supernatant from this step was subject to ultracentrifugation at 100,000 × *g* for 1 h at 4°C to yield a supernatant fraction containing soluble proteins and an insoluble pellet. The pellet was solubilized by agitation in 2% SDS at 100°C. Total protein concentration for both supernatant and pellet fractions was determined by BCA Protein Assay (Pierce Biotechnology, Rockford, IL), which was used to normalize protein loading onto 4--12% gradient SDS--PAGE gels (20 μg/lane for supernatant fractions, 5 μg/lane for pellet fractions). Proteins were electroblotted onto nitrocellulose membranes for Western blotting and probed with mouse anti-Aβ (6E10; Covance, Sydney, Australia) antibodies overnight at 1:1000 dilution. Immunodetection was performed using horseradish peroxidase--conjugated anti-mouse secondary antibodies (Jackson ImmunoResearch, West Grove, PA), chemiluminescence reagents (Bio-Rad, Sydney, Australia), and ChemiDoc MP charge-coupled device imaging system (Bio-Rad). Analysis and quantitation of Western blot images was performed using ImageJ, version 1.38 (National Institutes of Health, Bethesda, MD).

High-throughput transformation of the *S*. *cerevisiae* genome knockout collection
----------------------------------------------------------------------------------

Microtiter plates containing strains from the *S*. *cerevisiae* genome-wide deletion collection were replicated into 96-well plates containing 160 μl of YEPD medium/well and incubated at 30°C with shaking for 1 d. Cells were pelleted and resuspended in 20 μl of sterile MilliQ water before the addition of 160 μl of transformation mix/well (40% \[wt/vol\] PEG-3350, 100 mM lithium acetate, 1 mM EDTA, 10 mM Tris-HCl, pH 7.5, 20 ng/ml single-stranded herring sperm DNA, and 5 μg/well pAβ42-GFP plasmid DNA). Plates were incubated at 30°C overnight, followed by heat shock at 42°C for 30 min. Cells were pelleted, resuspended in 150 μl of SC medium (lacking uracil for selection of the pAβ42-GFP plasmid), and incubated at 30°C with shaking for 2 d. Further selection was performed by replicating cells into fresh 96-well plates (containing 150 μl/well of uracil-free SC media) and growing for 1 d. Strains were stored for later analysis by resuspension in 10% (vol/vol) glycerol and freezing at −80°C.

Epifluorescence and confocal microscopy, and the visualization of organelles
----------------------------------------------------------------------------

Fluorescence microscopy was performed using a Leica DM5500B microscope under 100× objective. Nuclear and mitochondrial DNA were visualized by staining cells with DAPI. Images were obtained and processed using the Leica Application Suite. Image overlays were performed using ImageJ, version 1.38 software. Confocal fluorescence microscopy was performed using an Olympus FV-1000 confocal microscope under 100× objective. GFP and DAPI images were visualized using 488- and 405-nm lasers, respectively. Three-dimensional confocal data analysis and image processing were performed using the Imaris 7.2 software package (Bitplane). The appearance of rod-like regions along the *z*-axis of Aβ42-GFP in the confocal image may be an artifact of limitation in imaging resolution along this *z*-axis.

Screening and analyzing knockout mutants for Aβ42-GFP fluorescence
------------------------------------------------------------------

Strains transformed with pAβ42-GFP were replicated and grown for 48 h with shaking at 30°C in microtiter plates containing 150 µl/well of induction medium. Strains were replicated in microtiter plates and grown for a further 24 h before Aβ42-GFP fluorescence was evaluated using fluorescence microscopy. A minimum of 900 cells per strain were examined for presence of Aβ42-GFP fluorescence. Mutant strains exhibiting altered fluorescence were subcultured in induction media and reexamined.

Positive strains were analyzed for overrepresentation of functional groups with Gene Ontology (GO) and MIPS databases using GO Biological Process, GO Molecular Function, and GO Cellular Component in the analysis. *S. cerevisiae* genes were mapped to human homologues using the HomoloGene database ([www.ncbi.nlm.nih.gov/sites/entrez?db=homologene](http://www.ncbi.nlm.nih.gov/sites/entrez?db=homologene)). All other analyses of *S. cerevisiae* genes and associated annotations were performed using the *Saccharomyces* Genome Database and associated tools ([www.yeastgenome.org](http://www.yeastgenome.org)).

Subcellular fractionation
-------------------------

Subcellular fractions of *S*. *cerevisiae* cells were prepared as previously described by [@B83] and the cross-contamination of the ER and mitochondrial fractions verified by Western blot analysis using antibodies against Wbp1p and Por1p, respectively. Cells expressing Aβ42-GFP were grown to exponential phase (OD~600~ of 1.5) in galactose medium, harvested, washed in distilled water, and converted to spheroplasts ([@B13]). Preparation of spheroplasts was performed using 2 mg Zymolyase 20T/g cell wet weight and incubating for 1.5 h at 30°C shaking (600 rpm). Spheroplasts were homogenized on ice using a Dounce homogenizer with a tight-fitting pestle and centrifuged to remove unbroken cells and nuclei. For preparation of crude mitochondrial fraction, cell lysates were centrifuged at 30,000 × *g* (30 min, 4°C). To enrich for mitochondria, the resulting pellet was thrice resuspended in breakage buffer, rehomogenized, and centrifuged. For preparation of crude ER microsomal fraction, the remaining supernatant was centrifuged at 45,000 × *g* (45 min; 4°C). To enrich for ER, the resulting pellet was resuspended in breakage buffer, rehomogenized, and centrifuged. To validate lack of cross-contamination of subcellular fractions, proteins from ER and mitochondrial fractions were precipitated with 50% trichloroacetic acid for 1 h on ice, and Western blot analysis was subsequently performed as described.

Statistical analysis
--------------------

Statistical analysis was performed using the unpaired Student\'s *t* test, using Prism 5 for Windows, version 5.02 (GraphPad Software). Data are presented as mean ± SD. Significant differences are indicated by a *p* value for data in the text and figures.
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Aβ

:   amyloid-β
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:   Alzheimer\'s disease
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:   phosphatidylcholine
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:   tricarboxylic acid
